other material
confidence high
sentiment positive
materiality 0.85
Edesa Biotech reports positive Phase 3 results for paridiprubart in ARDS; 28-day mortality reduced 13% absolute
Edesa Biotech, Inc.
- Paridiprubart + SOC reduced 28-day mortality to 39% vs 52% placebo (n=104; p<0.001): 13% absolute improvement, 25% relative risk reduction.
- Durable survival benefit at 60 days: 46% vs 59% mortality (p=0.003); 13% absolute improvement, 22% relative risk reduction.
- Paridiprubart arm showed 41% higher relative rate of clinical improvement (≥2-point WCSS improvement at Day 28; p=0.032).
- Safety data from >275 subjects: paridiprubart generally well-tolerated, consistent with prior profile.
- Paridiprubart also in U.S. government 'Just Breathe' study; program funded by Government of Canada's Strategic Innovation Fund.